Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Want to see SCNI full AI Analyst Report?
Top Page
Scinai Immunotherapeutics
(NASDAQ:SCNI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.69
▼(-11.67% Downside)
Action:ReiteratedDate:04/07/26
The score is primarily held down by weak financial performance (ongoing losses, negative gross profit, and continued cash burn) despite an improved capital structure with much lower debt. Technicals also remain negative with the stock below major moving averages and a negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
CDMO footprint expansion
Acquiring Recipharm Israel and the collaboration materially expand Scinai’s manufacturing footprint and technical scope across proteins, small molecules, peptides, antibodies and oligos. This builds an end-to-end CDMO pathway, diversifies revenue streams, and strengthens long-term client pipelines and tech‑transfer capabilities.
Negative Factors
Persistent negative cash flow
Operating and free cash flow remain meaningfully negative, indicating the business consumes cash to fund R&D and CDMO buildout. Continued cash burn forces reliance on external financing, which can dilute shareholders or constrain investment pacing, posing a durable funding risk absent material revenue or margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO footprint expansion
Acquiring Recipharm Israel and the collaboration materially expand Scinai’s manufacturing footprint and technical scope across proteins, small molecules, peptides, antibodies and oligos. This builds an end-to-end CDMO pathway, diversifies revenue streams, and strengthens long-term client pipelines and tech‑transfer capabilities.
Read all positive factors
Scinai Immunotherapeutics (SCNI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.24M
Dividend YieldN/A
Average Volume (3M)101.31K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth99.48%
EPS Growth-474.47%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,535,489
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit-0.86
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scinai Immunotherapeutics Business Overview & Revenue Model
Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel...
How the Company Makes Money
null...
Scinai Immunotherapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.15M | 1.31M | 658.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -2.65M | -580.00K | -512.67K | -559.80K | -747.65K |
| EBITDA | 8.80M | -6.53M | -6.99M | -9.19M | -10.50M | -10.39M |
| Net Income | 4.09M | -8.31M | 4.80M | -6.50M | -5.80M | -8.21M |
Balance Sheet | ||||||
| Total Assets | 11.84M | 11.63M | 13.45M | 17.47M | 27.07M | 32.04M |
| Cash, Cash Equivalents and Short-Term Investments | 989.00K | 1.66M | 1.96M | 4.87M | 14.07M | 17.37M |
| Total Debt | 2.36M | 2.27M | 2.09M | 20.56M | 21.54M | 29.23M |
| Total Liabilities | 3.98M | 3.52M | 3.47M | 22.04M | 28.83M | 31.05M |
| Stockholders Equity | 7.86M | 8.10M | 9.98M | -4.57M | -1.76M | 982.00K |
Cash Flow | ||||||
| Free Cash Flow | -5.71M | -6.05M | -6.35M | -10.02M | -8.10M | -7.57M |
| Operating Cash Flow | -5.69M | -6.03M | -6.33M | -9.38M | -7.26M | -7.43M |
| Investing Cash Flow | -16.02K | -24.00K | -12.00K | -637.00K | -836.00K | -139.00K |
| Financing Cash Flow | 3.59M | 5.77M | 3.44M | 1.09M | 6.78M | 21.43M |
Scinai Immunotherapeutics Technical Analysis
Negative
0.78
Price Trends
0.71
Negative
0.82
Negative
1.19
Negative
Market Momentum
-0.04
Negative
35.49
Neutral
37.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.71, and below the 200-day MA of 1.19, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 35.49 is Neutral, neither overbought nor oversold. The STOCH value of 37.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNI.
Scinai Immunotherapeutics Risk Analysis
Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scinai Immunotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
SCNI
Scinai Immunotherapeutics
0.64
-2.26
-77.79%
GTBP
GT Biopharma
0.38
-1.91
-83.32%
ADTX
Aditxt
0.14
-1,988.66
-99.99%
CERO
CERo Therapeutics Holdings
0.03
-15.77
-99.82%
PBM
Psyence Biomedical
6.69
-23.13
-77.57%
CDT
CDT Equity
2.10
-1,505.10
-99.86%
Scinai Immunotherapeutics Corporate Events
Scinai Immunotherapeutics Raises $2.61 Million in ADS and Warrant Financing to Expand CDMO and Immunotherapy Programs
Apr 27, 2026
On April 23, 2026, Scinai Immunotherapeutics Ltd. entered into a securities purchase agreement with institutional and accredited investors for a private placement of 5,208,333 American Depositary Shares at $0.48 per ADS, together with Series A and...
Scinai Immunotherapeutics Revises €12M FENG Bid and Extends PinCell Option Timeline
Mar 23, 2026
On March 2, 2026, Scinai Immunotherapeutics announced it had signed a second amendment to its binding option agreement to acquire Italian biotech PinCell S.r.l. and submitted a revised application under the European Funds for the Modern Economy SM...
Scinai Immunotherapeutics Faces Nasdaq Minimum Bid Price Deficiency, Given Until September to Regain Compliance
Mar 19, 2026
On March 16, 2026, Scinai Immunotherapeutics disclosed that it had received a Nasdaq notice on March 12, 2026 stating its American Depositary Shares had traded below the $1.00 minimum bid price for 30 consecutive business days, putting it out of c...
Scinai Wins Expanded Israel Innovation Authority Backing for Robotic Aseptic Platform
Feb 25, 2026
On February 25, 2026, Scinai Immunotherapeutics announced that the Israel Innovation Authority has expanded support for the company’s project to implement a robotic aseptic fill-and-finish platform, allowing Scinai to deploy the full NIS 5 m...
Scinai Immunotherapeutics Buys Recipharm Israel Unit, Seals Strategic CDMO Pact
Feb 17, 2026
On February 17, 2026, Scinai Immunotherapeutics completed the acquisition of Recipharm Israel Ltd., which operates a cGMP active pharmaceutical ingredient manufacturing site in Yavne, Israel, and signed a long-term strategic commercial collaborati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.